This study will investigate the safety and clinical efficacy of a novel doxycycline topical
formulation in subjects with Atopic Dermatitis (AD). The investigators hypothesize that daily
application of the study drug in AD subjects will reduce severity of the disease, by reducing
skin driven inflammation and restoring skin barrier function. The investigators will also
monitor the anti-microbial activity of this product on AD skin, as colonization with Staph
aureus is typically associated with disease severity.